Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Papillomavirus Infections 2Neoplasms 2Liver Neoplasms 2Liver Diseases 2Virus Diseases 1Stomach Neoplasms 1Rheumatic Diseases 1Primary Graft Dysfunction 1Liver Failure, Acute 1Liver Failure 1Head and Neck Neoplasms 1HIV Infections 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Irinotecan 6Gemcitabine 5130-nm albumin-bound paclitaxel 5Oxaliplatin 4Fluorouracil 4Capecitabine 4Bevacizumab 4Albumin-Bound Paclitaxel 4napabucasin 3Ocoxin 3Leucovorin 3pembrolizumab 2Sorafenib 2Paclitaxel 2Nivolumab 2Cyclophosphamide 2Cetuximab 2Bupivacaine 2Aspirin 2Ascorbic Acid 2trifluridine tipiracil drug combination 1trametinib 1pralsetinib 1penpulimab 1ozanimod 1linifanib 1hetrombopag 1halofantrine 1guadecitabine 1golotimod 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Digestive System Diseases × halofantrine × Clear all
NCT00827554 2016-04-01

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡